Navigation Links
Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device
Date:1/19/2012

ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ -- Terumo Cardiovascular Systems announced today that it has entered into an exclusive agreement with LAAx, Inc. to distribute the TigerPaw® System II, a left atrial appendage closure device in the U.S.

The TigerPaw System II is indicated for occlusion of the left atrial appendage under direct visualization, in conjunction with other open cardiac procedures.  It is new to the market following successful completion of a clinical trial.  During its clinical trial the TigerPaw System II provided 100% occlusion at both post-op and at 90 days.

Mark Sutter, President and CEO of Terumo Cardiovascular Systems, stated, "This expansion of our product portfolio is another example of Terumo CVS's commitment to the CV OR market.  The distribution agreement provides us with an excellent product that provides advantages over other offerings on the market and that cardiac surgeons need today.  We are proud of this new partnership with LAAx, Inc."

Bill Wheeler, President and CEO of LAAx, Inc., added, "Terumo's broad distribution network will be a tremendous asset.  We will work together to get the TigerPaw System II into the hands of cardiac surgeons who have not yet had access to a clinically proven, 100% occlusive left atrial appendage (LAA) closure device. This clinical outcome expectation will benefit patients who need to reduce the medical risks associated with a less than 100% closure of the LAA.  We are happy to offer that option. Risk mitigation is an important consideration for every cardiac surgeon who considers 100% occlusion to be the only acceptable medical outcome for LAA occlusion technologies."

About Terumo Cardiovascular Systems Corporation 
Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery market and is the U.S. distributor for Vascutek® Vascular Grafts. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts. It is one of several subsidiaries of Terumo Corporation of Japan which focus on cardiac and vascular specialties, including Terumo Heart, Inc., developer of a ventricular assist device and Vascutek, Ltd., manufacturer of a broad portfolio of vascular grafts. For more information, visit www.terumo-cvs.com.

About LAAx, Inc.
LAAx, Inc. is a medical device company, located in Livermore, CA, whose purpose is to develop leading edge technology for the effective occlusion and/or exclusion of the left atrial appendage. Additionally, LAAx, Inc. is committed to maintaining effective systems to manage quality and quality objectives which translate technology into medical devices that are safe, serve the needs of the patient and the physician, and provide a viable business opportunity. LAAx, Inc.'s global goal is to make a positive impact on both the quality and effectiveness of healthcare delivered worldwide.

 


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Americas Holding Acquires Onset Medical Corporation, a Leader in Innovative Sheath Technology Designed for Multiple, Minimally Invasive Clinical Applications
2. Terumo Corporation, A Global Leader In Medical Device Technology, Celebrates 90th Anniversary
3. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
4. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
5. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
6. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
7. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com released its first International ... of 70% when buying medication online from Canadian pharmacies verified in the PharmacyChecker ... other countries. The report (chart below) compares U.S. and foreign prices for 20 ...
(Date:4/21/2017)... ... 21, 2017 , ... Providing broad access to life-saving drugs and rewarding the ... better way to address this problem. , That was the message from Dana Goldman, ... at the University of Southern California, who served as the keynote speaker for Western ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... adolescents and young adults, has kicked off its 4th annual Forum for Innovative ... year’s theme is “Attachment Informed Therapy for Mental Health and Addiction.” , ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies ... project in the company’s esteemed VISION House demonstration project series. Manifesting the concept of ... of resources they need to live affordably and abundantly without unduly taxing the resources ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
Breaking Medicine News(10 mins):